{"protocolSection":{"identificationModule":{"nctId":"NCT02504372","orgStudyIdInfo":{"id":"3475-091"},"secondaryIdInfos":[{"id":"EORTC-1416-LCG","type":"OTHER","domain":"EORTC"},{"id":"163457","type":"REGISTRY","domain":"JAPIC-CTI"},{"id":"MK-3475-091","type":"OTHER","domain":"MSD"},{"id":"KEYNOTE-091","type":"OTHER","domain":"MSD"},{"id":"2023-509137-39-00","type":"REGISTRY","domain":"EU CT"},{"id":"U1111-1309-6051","type":"REGISTRY","domain":"UTN"},{"id":"2015-000575-27","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","officialTitle":"A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)","acronym":"PEARLS"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-01-24","type":"ACTUAL"},"completionDateStruct":{"date":"2026-01-21","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-07-20","studyFirstSubmitQcDate":"2015-07-20","studyFirstPostDateStruct":{"date":"2015-07-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2024-01-09","resultsFirstSubmitQcDate":"2024-02-13","resultsFirstPostDateStruct":{"date":"2024-02-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-02","lastUpdatePostDateStruct":{"date":"2025-09-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"collaborators":[{"name":"ETOP","class":"UNKNOWN"},{"name":"European Organisation for Research and Treatment of Cancer - EORTC","class":"NETWORK"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Non-small cell lung cancer (NSCLC)","Programmed Cell Death Receptor 1 (PD-1)","Programmed Cell Death Receptor Ligand 1 (PD-L1)","Programmed Cell Death Receptor Ligand (PDL)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1177,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pembrolizumab","type":"EXPERIMENTAL","description":"Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).","interventionNames":["Biological: Pembrolizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"IV infusion","armGroupLabels":["Pembrolizumab"],"otherNames":["MK-3475","KEYTRUDA®"]},{"type":"OTHER","name":"Placebo","description":"IV infusion","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease-Free Survival (DFS)","description":"DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","timeFrame":"Up to approximately 84 months"},{"measure":"DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%","description":"DFS in PDL-1 strong positive participants with TPS ≥50% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","timeFrame":"Up to approximately 84 months"}],"secondaryOutcomes":[{"measure":"DFS in PDL-1 Strong Positive Participants With TPS ≥1%","description":"DFS in PDL-1 strong positive participants with TPS ≥1% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","timeFrame":"Up to approximately 84 months"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death.","timeFrame":"Up to approximately 132 months"},{"measure":"OS in PDL-1 Strong Positive Participants With TPS ≥50%","description":"OS in PDL-1 Strong Positive Participants with TPS ≥50% was defined as the time from randomization to the date of death.","timeFrame":"Up to approximately 132 months"},{"measure":"OS in PDL-1 Strong Positive Participants With TPS ≥1%","description":"OS in PDL-1 Strong Positive Participants with TPS ≥1% was defined as the time from randomization to the date of death.","timeFrame":"Up to approximately 132 months"},{"measure":"Lung Cancer Specific Survival (LCSS)","description":"LCSS was defined as the time from randomization to the date of death (due to lung cancer specifically).","timeFrame":"Up to approximately 132 months"},{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who experienced an AE were reported.","timeFrame":"Up to approximately 22 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an AE","description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who discontinued study treatment due to an AE were reported.","timeFrame":"Up to approximately 19 months"}],"otherOutcomes":[{"measure":"DFS at 68 Months","description":"DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","timeFrame":"Up to approximately 68 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathological diagnosis of NSCLC confirmed at surgery, any histology. Participants with two synchronous primary non-small cell lung cancers are excluded from the study\n* Union for International Cancer Control (UICC) v7 Stage IB with T ≥ 4 cm, II-IIIA NSCLC after complete surgical resection with resection margins proved microscopically free of disease (R0). Carcinoma in situ can be present at the bronchial margin\n* Available tumor sample obtained at surgical resection for programmed cell death ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate organ function performed within 10 days of treatment initiation\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first infusion of study medication). If the urine test cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the participant to be eligible\n* Female participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity starting with the first infusion of study treatment through 120 days after the last infusion of study treatment\n* Female participants who are breast feeding must discontinue nursing prior to the first infusion of study medication and until 120 days after the last infusion study treatment\n* Male participants must agree to use an adequate method of contraception starting with the first infusion of study treatment through 120 days after the last infusion of study treatment\n* Absence of severe comorbidities that in the opinion of the Investigator might hamper the participation to the study and/or the treatment administration\n* No prior or planned neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant chemotherapy for the current malignancy is allowed\n\nExclusion Criteria:\n\n* Evidence of disease at clinical examination and/or baseline radiological assessment as documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical examination\n* More than 4 cycles of adjuvant therapy\n* Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2, anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators or any other immune-modulating agents\n* Live vaccine within 30 days prior to the first infusion of study treatment\n* Current participation or treatment with an investigational agent or use of an investigational device within 4 weeks of the first infusion of study treatment\n* History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No known active Hepatitis B or C\n* Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 3 days prior to the first infusion of study treatment\n* History of interstitial lung disease or (non-infectious) pneumonitis that required oral or IV steroids (other than COPD exacerbation) or current pneumonitis\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* History of a hematologic or primary solid tumor malignancy, unless in remission for at least 5 years with the exception of pT1-2 prostatic cancer Gleason score \\< 6, superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the cervix\n* Previous allogeneic tissue/solid organ transplant\n* Active infection requiring therapy\n* Surgery- or chemotherapy-related toxicity (non-hematological) not resolved to Grade 1 with the exception of alopecia, fatigue, neuropathy and lack of appetite /nausea\n* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last infusion of study treatment\n* Participant will not be eligible if the participant is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective site Review Board approval is given allowing exception to this criterion for a specific participant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"36108662","type":"DERIVED","citation":"O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12."}],"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://merckclinicaltrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf","url":"https://externaldatasharing-msd.com/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","groups":[{"id":"FG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"FG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"590"},{"groupId":"FG001","numSubjects":"587"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"580"},{"groupId":"FG001","numSubjects":"581"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"590"},{"groupId":"FG001","numSubjects":"587"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"154"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal of consent","reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Participants ongoing","reasons":[{"groupId":"FG000","numSubjects":"429"},{"groupId":"FG001","numSubjects":"415"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","groups":[{"id":"BG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"BG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"64.1","spread":"8.5"},{"groupId":"BG001","value":"64.5","spread":"8.4"},{"groupId":"BG002","value":"64.3","spread":"8.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"373"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"401"},{"groupId":"BG001","value":"403"},{"groupId":"BG002","value":"804"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"214"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"450"},{"groupId":"BG001","value":"455"},{"groupId":"BG002","value":"905"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"41"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}]}]},{"title":"Disease Stage at Baseline","description":"Participants were classified per American Joint Committee on Cancer Manual Edition 7th (AJCC V7) based on TNM classification where T refers to size and extent of primary tumor and if it invaded nearby tissue, N refers to location of nearby lymph nodes that have cancer and M refers to distant metastasis (spread of cancer to other parts). In stages I, II and III the cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues. In stage IV, the cancer has spread to distant parts of the body. Higher numbers mean the cancer is more advanced.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Stage IB","measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"172"}]},{"title":"Stage II","measurements":[{"groupId":"BG000","value":"330"},{"groupId":"BG001","value":"338"},{"groupId":"BG002","value":"668"}]},{"title":"Stage IIIA","measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"160"},{"groupId":"BG002","value":"335"}]},{"title":"Stage IV","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Status at Baseline","description":"Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from a biopsy. Participants with a tumor proportion score (TPS) were classified as follows: \\<1% = PD-L1 negative, 1-49% = PD-L1 weakly positive; and ≥50% = PD-L1 strongly positive.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"TPS <1%","measurements":[{"groupId":"BG000","value":"233"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"465"}]},{"title":"TPS 1-49%","measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"379"}]},{"title":"TPS ≥50%","measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"333"}]}]}]},{"title":"Adjuvant Chemotherapy at Baseline","description":"Participants were classified per receiving of standard adjuvant chemotherapy at baseline: Yes or No.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"506"},{"groupId":"BG001","value":"504"},{"groupId":"BG002","value":"1010"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"167"}]}]}]},{"title":"Geographic region","description":"Participants were classified based on their geographic region as those from: Western Europe, Easter Europe, Asia and Rest of the world.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Western Europe","measurements":[{"groupId":"BG000","value":"303"},{"groupId":"BG001","value":"301"},{"groupId":"BG002","value":"604"}]},{"title":"Eastern Europe","measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"229"}]},{"title":"Rest of the World","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"133"}]},{"title":"Asia","measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"211"}]}]}]},{"title":"Tumor Histology","description":"Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"416"}]},{"title":"Non-squamous","measurements":[{"groupId":"BG000","value":"398"},{"groupId":"BG001","value":"363"},{"groupId":"BG002","value":"761"}]}]}]},{"title":"Smoking status","description":"Participants were classified per centers of disease control and prevention (CDC) as: Never smoker (smoked fewer than 100 cigarettes in his/her lifetime), former smoker (smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview. and current smoker (smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes) at baseline.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}]}],"categories":[{"title":"Never smoker","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"153"}]},{"title":"Former smoker","measurements":[{"groupId":"BG000","value":"428"},{"groupId":"BG001","value":"431"},{"groupId":"BG002","value":"859"}]},{"title":"Current smoker","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"165"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-Free Survival (DFS)","description":"DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","populationDescription":"All randomized participants. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 84 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"590"},{"groupId":"OG001","value":"587"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","lowerLimit":"46.2","upperLimit":"67.0"},{"groupId":"OG001","value":"43.0","lowerLimit":"35.0","upperLimit":"51.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"0.96","estimateComment":"HR and 95% confidence interval (95%CI) were based on multivariate Cox regression model with treatment adjusted by stage, PD-L1 status, adjuvant chemotherapy, region, histology, and smoking status."}]},{"type":"PRIMARY","title":"DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%","description":"DFS in PDL-1 strong positive participants with TPS ≥50% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","populationDescription":"All randomized PDL-1 strong positive participants with TPS ≥50%. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 84 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"165"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","lowerLimit":"47.8","upperLimit":"NA","comment":"NA = Upper limit DFS was not reached at the time of last disease assessment due to insufficient number of participants with events."},{"groupId":"OG001","value":"47.6","lowerLimit":"36.4","upperLimit":"NA","comment":"NA = Upper limit DFS was not reached at the time of last disease assessment due to insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.13499","statisticalMethod":"Regression, Cox","statisticalComment":"One-sided p-value was based on the permutation test with multivariate Cox regression model.","paramType":"Hazard Ratio (HR)","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"1.16","estimateComment":"HR and 95% confidence interval (95%CI) were based on multivariate Cox regression model with treatment adjusted by stage, PD-L1 status, adjuvant chemotherapy, region, histology, and smoking status."}]},{"type":"SECONDARY","title":"DFS in PDL-1 Strong Positive Participants With TPS ≥1%","description":"DFS in PDL-1 strong positive participants with TPS ≥1% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","populationDescription":"All randomized PDL-1 strong positive participants with TPS ≥1%. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 84 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","lowerLimit":"46.2","upperLimit":"76.7"},{"groupId":"OG001","value":"42.8","lowerLimit":"35.0","upperLimit":"57.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.01327","statisticalMethod":"Regression, Cox","statisticalComment":"One-sided p-value was based on the permutation test with multivariate Cox regression model.","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"0.97","estimateComment":"HR and 95% confidence interval (95%CI) were based on multivariate Cox regression model with treatment adjusted by stage, PD-L1 status, adjuvant chemotherapy, region, histology, and smoking status."}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-02","timeFrame":"Up to approximately 132 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"OS in PDL-1 Strong Positive Participants With TPS ≥50%","description":"OS in PDL-1 Strong Positive Participants with TPS ≥50% was defined as the time from randomization to the date of death.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-02","timeFrame":"Up to approximately 132 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"OS in PDL-1 Strong Positive Participants With TPS ≥1%","description":"OS in PDL-1 Strong Positive Participants with TPS ≥1% was defined as the time from randomization to the date of death.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-02","timeFrame":"Up to approximately 132 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Lung Cancer Specific Survival (LCSS)","description":"LCSS was defined as the time from randomization to the date of death (due to lung cancer specifically).","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-02","timeFrame":"Up to approximately 132 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who experienced an AE were reported.","populationDescription":"All randomized participants who received at least one dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 22 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"581"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"529"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Treatment Due to an AE","description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who discontinued study treatment due to an AE were reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 19 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"581"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"34"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"DFS at 68 Months","description":"DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.","populationDescription":"All randomized participants. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 68 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year."},{"id":"OG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"590"},{"groupId":"OG001","value":"587"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","lowerLimit":"39.2","upperLimit":"NA","comment":"NA = Upper limit DFS was not reached at the time of last disease assessment due to insufficient number of participants with events."},{"groupId":"OG001","value":"42.0","lowerLimit":"31.3","upperLimit":"NA","comment":"NA = Upper limit DFS was not reached at the time of last disease assessment due to insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.00143","statisticalMethod":"Regression, Cox","statisticalComment":"One-sided p-value was based on the permutation test with multivariate Cox regression model.","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"0.91","estimateComment":"HR and 95% confidence interval (95%CI) were based on multivariate Cox regression model with treatment adjusted by stage, PD-L1 status, adjuvant chemotherapy, region, histology, and smoking status."}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 86 months","description":"All-cause mortality was reported on all randomized participants. Serious and non-serious adverse events were reported on all randomized participants who received at least one dose of study treatment. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant.","eventGroups":[{"id":"EG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year.","deathsNumAffected":136,"deathsNumAtRisk":590,"seriousNumAffected":142,"seriousNumAtRisk":580,"otherNumAffected":510,"otherNumAtRisk":580},{"id":"EG001","title":"Placebo","description":"Participants received placebo, IV, every 3 weeks, for one year.","deathsNumAffected":154,"deathsNumAtRisk":587,"seriousNumAffected":90,"seriousNumAtRisk":581,"otherNumAffected":458,"otherNumAtRisk":581}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Atrial tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":581}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Glucocorticoid deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":580},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":581}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Erosive oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":581}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":581}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Sarcoidosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Lower respiratory tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Penile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":580},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":581}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Post procedural pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":581}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Incision site discharge","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Sternal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":581}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Back disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Polymyalgia rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Sarcopenia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Adenocarcinoma gastric","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Adenocarcinoma pancreas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Clear cell renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Haemangioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Neuroendocrine tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Oesophageal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":581}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Prostate cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Rectal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":581}]},{"term":"Small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Small intestine carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Squamous cell carcinoma of the tongue","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Superficial spreading melanoma stage unspecified","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Tonsil cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Tracheal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Ureteric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Brain stem stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Dysaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Intensive care unit acquired weakness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Retrograde amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Superior sagittal sinus thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Device dislocation","organSystem":"Product Issues","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":581}]},{"term":"Neurosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Bronchial haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":580},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":581}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":580},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":581}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Scar pain","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Aortic aneurysm rupture","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":581}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]},{"term":"Giant cell arteritis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":580},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":581}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":580},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":581}]}],"otherEvents":[{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":62,"numAtRisk":580},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":581}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":148,"numAffected":120,"numAtRisk":580},{"groupId":"EG001","numEvents":29,"numAffected":27,"numAtRisk":581}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":35,"numAtRisk":580},{"groupId":"EG001","numEvents":53,"numAffected":41,"numAtRisk":581}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":179,"numAffected":104,"numAtRisk":580},{"groupId":"EG001","numEvents":160,"numAffected":82,"numAtRisk":581}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":52,"numAtRisk":580},{"groupId":"EG001","numEvents":48,"numAffected":37,"numAtRisk":581}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":44,"numAtRisk":580},{"groupId":"EG001","numEvents":39,"numAffected":32,"numAtRisk":581}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":131,"numAffected":96,"numAtRisk":580},{"groupId":"EG001","numEvents":118,"numAffected":89,"numAtRisk":581}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":34,"numAtRisk":580},{"groupId":"EG001","numEvents":36,"numAffected":32,"numAtRisk":581}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":31,"numAtRisk":580},{"groupId":"EG001","numEvents":48,"numAffected":32,"numAtRisk":581}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":50,"numAtRisk":580},{"groupId":"EG001","numEvents":44,"numAffected":32,"numAtRisk":581}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":52,"numAtRisk":580},{"groupId":"EG001","numEvents":68,"numAffected":55,"numAtRisk":581}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":75,"numAffected":46,"numAtRisk":580},{"groupId":"EG001","numEvents":42,"numAffected":34,"numAtRisk":581}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":41,"numAtRisk":580},{"groupId":"EG001","numEvents":40,"numAffected":31,"numAtRisk":581}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":38,"numAtRisk":580},{"groupId":"EG001","numEvents":52,"numAffected":32,"numAtRisk":581}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":39,"numAtRisk":580},{"groupId":"EG001","numEvents":36,"numAffected":25,"numAtRisk":581}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":260,"numAffected":132,"numAtRisk":580},{"groupId":"EG001","numEvents":314,"numAffected":168,"numAtRisk":581}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":41,"numAtRisk":580},{"groupId":"EG001","numEvents":28,"numAffected":26,"numAtRisk":581}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":152,"numAffected":107,"numAtRisk":580},{"groupId":"EG001","numEvents":99,"numAffected":72,"numAtRisk":581}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":45,"numAtRisk":580},{"groupId":"EG001","numEvents":57,"numAffected":46,"numAtRisk":581}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":37,"numAtRisk":580},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":581}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":580},{"groupId":"EG001","numEvents":38,"numAffected":31,"numAtRisk":581}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":45,"numAtRisk":580},{"groupId":"EG001","numEvents":60,"numAffected":46,"numAtRisk":581}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":580},{"groupId":"EG001","numEvents":39,"numAffected":32,"numAtRisk":581}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":87,"numAtRisk":580},{"groupId":"EG001","numEvents":130,"numAffected":98,"numAtRisk":581}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":87,"numAffected":66,"numAtRisk":580},{"groupId":"EG001","numEvents":91,"numAffected":72,"numAtRisk":581}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":32,"numAtRisk":580},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":581}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":37,"numAtRisk":580},{"groupId":"EG001","numEvents":18,"numAffected":15,"numAtRisk":581}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":31,"numAtRisk":580},{"groupId":"EG001","numEvents":25,"numAffected":21,"numAtRisk":581}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":167,"numAffected":125,"numAtRisk":580},{"groupId":"EG001","numEvents":115,"numAffected":74,"numAtRisk":581}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":49,"numAtRisk":580},{"groupId":"EG001","numEvents":37,"numAffected":29,"numAtRisk":581}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":43,"numAtRisk":580},{"groupId":"EG001","numEvents":27,"numAffected":20,"numAtRisk":581}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":160,"numAffected":67,"numAtRisk":580},{"groupId":"EG001","numEvents":184,"numAffected":74,"numAtRisk":581}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 30 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-09-23","uploadDate":"2024-01-09T16:43","filename":"Prot_SAP_000.pdf","size":2300323}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","Estonia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Latvia","Netherlands","Peru","Poland","Portugal","Russia","Slovenia","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"}]}},"hasResults":true}